<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pain Res</journal-id><journal-id journal-id-type="iso-abbrev">J Pain Res</journal-id><journal-id journal-id-type="publisher-id">Journal of Pain Research</journal-id><journal-title-group><journal-title>Journal of Pain Research</journal-title></journal-title-group><issn pub-type="epub">1178-7090</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28243144</article-id><article-id pub-id-type="pmc">5317309</article-id><article-id pub-id-type="doi">10.2147/JPR.S123045</article-id><article-id pub-id-type="publisher-id">jpr-10-397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trial Report</subject></subj-group></article-categories><title-group><article-title>A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goldberg</surname><given-names>Henrique</given-names></name><xref ref-type="aff" rid="af1-jpr-10-397">1</xref></contrib><contrib contrib-type="author"><name><surname>Mibielli</surname><given-names>Marco Antonio</given-names></name><xref ref-type="aff" rid="af2-jpr-10-397">2</xref></contrib><contrib contrib-type="author"><name><surname>Nunes</surname><given-names>Carlos Pereira</given-names></name><xref ref-type="aff" rid="af2-jpr-10-397">2</xref></contrib><contrib contrib-type="author"><name><surname>Goldberg</surname><given-names>Stephanie Wrobel</given-names></name><xref ref-type="aff" rid="af3-jpr-10-397">3</xref></contrib><contrib contrib-type="author"><name><surname>Buchman</surname><given-names>Luiz</given-names></name><xref ref-type="aff" rid="af4-jpr-10-397">4</xref></contrib><contrib contrib-type="author"><name><surname>Mezitis</surname><given-names>Spyros GE</given-names></name><xref ref-type="aff" rid="af5-jpr-10-397">5</xref></contrib><contrib contrib-type="author"><name><surname>Rzetelna</surname><given-names>Helio</given-names></name><xref ref-type="aff" rid="af6-jpr-10-397">6</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="af2-jpr-10-397">2</xref></contrib><contrib contrib-type="author"><name><surname>Geller</surname><given-names>Mauro</given-names></name><xref ref-type="aff" rid="af2-jpr-10-397">2</xref><xref ref-type="corresp" rid="c1-jpr-10-397"/></contrib><contrib contrib-type="author"><name><surname>Wajnsztajn</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="af7-jpr-10-397">7</xref></contrib></contrib-group><aff id="af1-jpr-10-397"><label>1</label>UERJ Medical School, Rio de Janeiro, Brazil</aff><aff id="af2-jpr-10-397"><label>2</label>UNIFESO Medical School, Teres&#x000f3;polis, Brazil</aff><aff id="af3-jpr-10-397"><label>3</label>Washington University School of Medicine, St Louis, MO, USA</aff><aff id="af4-jpr-10-397"><label>4</label>Instituto de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o M&#x000e9;dica Carlos Chagas (ICC), Rio de Janeiro, Brazil</aff><aff id="af5-jpr-10-397"><label>5</label>New York-Presbyterian Hospital/Weill-Cornell Medical Center, New York, NY, USA</aff><aff id="af6-jpr-10-397"><label>6</label>Santa Casa da Miseric&#x000f3;rdia do Rio de Janeiro, Rio de Janeiro, Brazil</aff><aff id="af7-jpr-10-397"><label>7</label>New York-Presbyterian Hospital/Columbia University Medical Center, Neurology, New York, NY, USA</aff><author-notes><corresp id="c1-jpr-10-397">Correspondence: Mauro Geller, UNIFESO Medical School, Av. Ataulfo de Paiva, 135 sl. 1104 Rio de Janeiro &#x02013; RJ &#x02013; Brazil 22440-030, Tel +55 21 3875 6660, Fax +55 21 2259 3395, Email <email>maurogeller@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2017</year></pub-date><volume>10</volume><fpage>397</fpage><lpage>404</lpage><permissions><copyright-statement>&#x000a9; 2017 Goldberg et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Context</title><p>This paper reports on the results of treatment of compressive neuralgia using a combination of nucleotides (uridine triphosphate trisodium [UTP] and cytidine monophosphate disodium [CMP]) and vitamin B<sub>12</sub>.</p></sec><sec><title>Objectives</title><p>To assess the safety and efficacy of the combination of nucleotides (UTP and CMP) and vitamin B<sub>12</sub> in patients presenting with neuralgia arising from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects with isolated administration of vitamin B<sub>12</sub>.</p></sec><sec><title>Methods</title><p>A randomized, double-blind, controlled trial, consisting of a 30-day oral treatment period: Group A (n=200) receiving nucleotides + vitamin B<sub>12,</sub> and Group B (n=200) receiving vitamin B<sub>12</sub> alone. The primary study endpoint was the percentage of subjects presenting pain visual analog scale (VAS) scores &#x02264;20 at end of study treatment period. Secondary study endpoints included the percentage of subjects presenting improvement &#x02265;5 points on the patient functionality questionnaire (PFQ); percentage of subjects presenting pain reduction (reduction in VAS scores at study end in relation to pretreatment); and number of subjects presenting adverse events.</p></sec><sec><title>Results</title><p>The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the combination of nucleotides + vitamin B<sub>12</sub>, with a statistically significant superiority of the combination in pain reduction (evidenced by VAS scores). There were adverse events in both treatment groups, but these were transitory and no severe adverse event was recorded during the study period. Safety parameters were maintained throughout the study in both treatment groups.</p></sec><sec><title>Conclusion</title><p>The combination of uridine, cytidine, and vitamin B<sub>12</sub> was safe and effective in the treatment of neuralgias arising from neural compression associated with degenerative orthopedic alterations and trauma.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>uridine triphosphate trisodium</kwd><kwd>cytidine monophosphate disodium</kwd><kwd>hydroxocobalamin</kwd><kwd>compressive neuralgia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Uridine and cytidine are substances belonging to the pyrimidine nucleotide family, which in turn comprises one of four main classes of biological molecules (along with carbohydrates, lipids, and proteins) that play several fundamental roles in cellular metabolism. Aside from being components of DNA and participating in genome transcription and translation, functions of these nucleotides include energy transfer for chemical bonding, intracellular signaling, neurotransmission, and transfer of biochemical radicals from intermediate metabolism.<xref rid="b1-jpr-10-397" ref-type="bibr">1</xref></p><p>Vitamin B<sub>12</sub> is essential in the human body for growth and maintenance of a variety of processes, including cell reproduction and synthesis of myelin and nucleoproteins, and must be supplied from an exogenous source.<xref rid="b2-jpr-10-397" ref-type="bibr">2</xref> Adequate vitamin B<sub>12</sub> levels in the body depend on adequate ingestion and absorption (requiring an acid-pepsin complex in the stomach that releases cobalamin from its binding proteins, pancreatic proteins that release cobalamin from the R factor bond, secretion of intrinsic factor by gastric parietal cells in order to bind cobalamin, and the presence of cobalamin and intrinsic factor receptors in the ileum.<xref rid="b3-jpr-10-397" ref-type="bibr">3</xref>,<xref rid="b4-jpr-10-397" ref-type="bibr">4</xref> Vitamin B<sub>12</sub> is important to nerve metabolism via the remethylation of homocysteine to methionine for de novo synthesis of s-Adenosyl methionine.<xref rid="b5-jpr-10-397" ref-type="bibr">5</xref> Vitamin B<sub>12</sub> deficiency can be caused by numerous factors, usually some combination of inadequate ingestion and absorption.<xref rid="b6-jpr-10-397" ref-type="bibr">6</xref> Deficiency can lead to megaloblastic anemia and neurological alterations, the latter likely linked to the absence of s-Adenosyl methionine formation.<xref rid="b7-jpr-10-397" ref-type="bibr">7</xref>, <xref rid="b8-jpr-10-397" ref-type="bibr">8</xref></p><p>This trial assessed treatment outcomes following administration of a combination of uridine triphosphate trisodium (UTP), cytidine monophosphate disodium (CMP), and vitamin B<sub>12</sub> in the treatment of patients with compressive neuralgias. There is a body of clinical and preclinical evidence in the literature, supporting use of CMP and UTP in neuropathic pain, with potential symptomatic benefits.<xref rid="b9-jpr-10-397" ref-type="bibr">9</xref>&#x02013;<xref rid="b22-jpr-10-397" ref-type="bibr">22</xref></p><p>Several preclinical studies of peripheral neuropathies of varying etiologies have indicated beneficial effects of UTP and CMP administration in situations such as experimentally induced crush injury. Reported preclinical observations include accelerated nerve and muscle fiber regeneration, increased nerve conduction velocity, increased levels of neuritic protein neurofilaments, increased axon myelin surface area and thickness, and increased levels of neuronal cell membrane phospholipids phosphatidylcholine and phosphatidylethanolamine following nucleotide administration.<xref rid="b19-jpr-10-397" ref-type="bibr">19</xref>&#x02013;<xref rid="b22-jpr-10-397" ref-type="bibr">22</xref> In the clinical setting, the combination of UTP and CMP with vitamin B<sub>12</sub> has been investigated in several painful conditions with favorable results, among which are diabetic neuropathy, acute non-traumatic pain, lumbar pain, cervical pain, and traumatic-compressive lesions.<xref rid="b10-jpr-10-397" ref-type="bibr">10</xref>&#x02013;<xref rid="b13-jpr-10-397" ref-type="bibr">13</xref>, <xref rid="b18-jpr-10-397" ref-type="bibr">18</xref></p></sec><sec><title>Objectives</title><p>The objectives of this study were to assess the safety and efficacy of the combination of nucleotides (UTP and CMP) and vitamin B<sub>12</sub> in patients presenting with neuralgia arising from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects with isolated administration of vitamin B<sub>12</sub>.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This was a randomized, double-blind, comparative, controlled trial performed at UNIFESO Medical School facilities and hospital. The study was registered with the Brazilian National Database GGMED/GESF-ANVISA under the following numbers: NOTIFICA&#x000c7;&#x000c3;O EM PESQUISA CL&#x000cd;NICA N&#x000ba; 61/2014 Expediente do CE: 0331070141. After study approval by the UNIFESO ethical committee (approval no 509.682) and written informed consent of all participants, subjects meeting inclusion criteria were randomized to a 30-day oral treatment period. Inclusion criteria included patients of both genders, &#x02265;18 years of age, with a clinical presentation of degenerative orthopedic alteration with neural compression. Female patients performed a urine pregnancy test prior to inclusion and were required to maintain adequate birth control throughout the study period. Exclusion criteria included need for surgical treatment and need for other analgesics.</p><p>Enrolled subjects were randomized by order of arrival to the study center into two treatment groups: Group A received the combination of nucleotides and vitamin B<sub>12,</sub> while subjects in Group B received vitamin B<sub>12</sub> monotherapy. The study drug and treatment regimen was two capsules, three times per day for Group A. Each capsule contained: CMP 2.5 mg; UTP 1.5 mg; and hydroxocobalamin 1.0 mg. Study treatment regimen for subjects in Group B was two capsules, three times per day, each capsule contained hydroxocobalamin 1.0 mg. There was no visible difference between the study drugs, in accordance with blinding procedures for double-blind trials. Subjects were instructed to swallow the capsules whole at breakfast, lunch, and dinner.</p><p>The study hypothesis was that the combination of nucleotides and vitamin B<sub>12</sub> would show superior efficacy in relation to B<sub>12</sub> monotherapy. The study protocol outlined three patient visits to the study center: pretreatment for screening, randomization, and study drug distribution; visit two took place after 15 days of treatment; and visit three occurred at the end of the 30-day treatment period. At each of these study visits, subjects underwent a series of efficacy and tolerability assessments.</p><p>Efficacy assessments included a 100 visual analog pain scale (VAS), and the Patient Functionality Questionnaire (PFQ), a 12-item yes or no questionnaire about management of daily needs. The assessment included sleep quality, need to rest, ability to get up, standing and climbing stairs, washing, drying, and dressing, picking up things from the floor, changing posture, carrying weight, and need for assistance from other people. At each assessment, the patient and the investigating physician also evaluated the patient&#x02019;s overall condition on a scale of 1&#x02013;10 points. Safety assessments took into account vital signs at each assessment and occurrence, severity, and duration of any adverse effects, including changes in laboratory tests.</p><p>The primary study endpoint was the percentage of subjects presenting VAS &#x02264;20 mm at end of study treatment period. Secondary study endpoints included the percentage of subjects presenting improvement &#x02265;5 points on the PFQ; percentage of subjects presenting pain reduction (reduction in VAS scores at study end in relation to pretreatment); and number of subjects presenting adverse events.</p><p>Study sample size took into account the results of a previous study,<xref rid="b10-jpr-10-397" ref-type="bibr">10</xref> evaluating 80 subjects (40 per treatment group), in which mean VAS scores at end of treatment were 21.11 in the combination group versus 41.75 in the B<sub>12</sub> monotherapy group. Thus, a study sample size of 400 was determined, taking into account the mean between group difference of 20.6mm and standard deviation of 10.3mm, from the previous study, with a standard error of 1.03. The 95% confidence interval was 18.58&#x02013;22.62, with a power of 1.0 and a two-tailed alpha of 0.05. Data were statistically analyzed using the software GraphPad Prism 5.0. Overall clinical efficacy and tolerability were analyzed via comparison of the results of each assessment in relation to pretreatment values, within and between treatment groups. For categorical variables, we used the &#x003c7;<sup>2</sup> or Fisher&#x02019;s test, while continuous variables were analyzed using the repeated measures ANOVA or Student&#x02019;s <italic>t</italic>-test.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 400 subjects were randomized to treatment, with 200 subjects per treatment group. <xref ref-type="fig" rid="f1-jpr-10-397">Figure 1</xref> shows the flow of subjects through the trial. No significant between-group differences were noted at pretreatment in the demographic data and pretreatment characteristics of the study population, as summarized in <xref ref-type="table" rid="t1-jpr-10-397">Table 1</xref>.</p><p>The safety measures monitored during the study are summarized in <xref ref-type="table" rid="t2-jpr-10-397">Table 2</xref>. Pretreatment safety measures did not vary significantly between Groups A and B: weight (<italic>p</italic>=0.148), body mass index (BMI) (<italic>p</italic>=0.532), blood pressure (<italic>p</italic>=1.0 for systolic blood pressure and <italic>p</italic>=0.849 for diastolic blood pressure), and heart rate (<italic>p</italic>=0.413). Throughout the treatment period within the treatment groups, with the exception of systolic blood pressure in both groups and diastolic blood pressure in Group B, there was no statistically significant change in weight (Group A, <italic>p</italic>=0.855; Group B, <italic>p</italic> =0.0603), BMI (Group A, <italic>p</italic> =0.6; Group B, <italic>p</italic> =0.257), blood pressure (Group A, <italic>p</italic> = 0.0013 for systolic blood pressure and <italic>p</italic>=0.133 for diastolic blood pressure; Group B, <italic>p</italic> =0.0046 for systolic blood pressure and <italic>p</italic>=0.0032 for diastolic blood pressure), and pulse (Group A, <italic>p</italic>=0.541; Group B, <italic>p</italic>=0.337).</p><p>Pretreatment PFQ scores were significantly lower among patients in Group B (median for Group A, 9.0; median for Group B, 8.0; <italic>p</italic>=0.0036). Median PFQ scores were 5.0 at visit two in both treatment groups and 0.0 at visit three in both treatment groups. Both groups showed statistically significant improvement at the end of the study in relation to pretreatment PFQ scores (<italic>p</italic>&#x0003c;0.0001 for both treatment groups). In relation to the secondary study endpoint, there was no between-group difference in the percentage of subjects presenting improvement &#x02265;5 points on the PFQ (<italic>p</italic>=0.135).</p><p>Pretreatment patient overall assessment scores were homogenous between treatment groups (<italic>p</italic>=0.29). At visits two and three, the scores of this assessment improved within each treatment group, but Group A patients showed a greater improvement in scores at both visit two (<italic>p</italic>=0.014) and visit three (<italic>p</italic>=0.0024) in comparison to Group B scores (<xref ref-type="fig" rid="f2-jpr-10-397">Figure 2</xref>). Physician overall assessment scores were also homogenous between treatment groups at pretreatment (<italic>p</italic>=0.717), but at visits two and three scores were significantly lower in Group A as compared to Group B (<italic>p</italic>=0.0029 for visit two and <italic>p</italic>=0.006 for visit three) (<xref ref-type="fig" rid="f3-jpr-10-397">Figure 3</xref>).</p><p>At pretreatment, mean VAS scores among the patients in Group A was 51.26mm (&#x000b1;12.38) while in Group B mean pretreatment VAS score was 51.06 (&#x000b1;11.72) (<italic>p</italic>=0.87). Visit two VAS scores for Group A and Group B were 29.86 mm (&#x000b1;12.94) and 33.88 mm (&#x000b1;11.86) (<italic>p</italic>=0.0014); At visit three, mean Group A VAS scores were 16.06 mm (&#x000b1;12.03) and 20.40 mm (&#x000b1;11.42) for Group B (<italic>p</italic>=0.0003). The percentage of subjects presenting VAS scores &#x02264;20 mm (primary study endpoint) at visit three was significantly higher in Group A as compared to Group B (<italic>p</italic>=0.0425). Within the treatment groups, VAS score reduction was statistically significant for both Group A and Group B (<italic>p</italic>&#x0003c;0.0001 for both groups) (<xref ref-type="fig" rid="f4-jpr-10-397">Figure 4</xref>).</p><p>Adverse events were recorded in both treatment groups, though for the most part these were not serious and were transient. <xref ref-type="table" rid="t3-jpr-10-397">Table 3</xref> summarizes the adverse events determined by the investigating physician to be related to the study drug. There was no between-group difference in the percentage of subjects presenting adverse events during the treatment period (<italic>p</italic>=0.6009).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>We report the results of a clinical trial using the combination of uridine, cytidine, and vitamin B<sub>12</sub> in the treatment of neuralgias caused by degenerative orthopedic alterations with neural compression. This combination is commercially available in Brazil under the brand name Etna<sup>&#x000ae;</sup>. The combination of the nucleotides with vitamin B<sub>12</sub> yielded a more significant pain reduction as measured by the VAS. Assessments performed by both the patients and the investigating physician had higher scores after 15 and 30 days of treatment among subjects treated with the combination. Treatment with the combination and with the control of vitamin B<sub>12</sub> monotherapy resulted in significant improvement in patient functionality throughout the treatment period, as measured by the patient functionality questionnaire.</p><p>The findings of this study are in agreement with those previously described in the literature. A previous study performed by Goldberg et al (2009) assessed the use of this combination in the treatment of back pain and hip pain, reporting significant reduction in pain assessments as well as functionality.<xref rid="b10-jpr-10-397" ref-type="bibr">10</xref> As with the study of Goldberg and also another recent study in alcoholic polyneuropathy in which the authors compared the use of the combination of UTP + CMP + vitamin B<sub>12</sub> with the use of vitamin B<sub>12</sub> monotherapy,<xref rid="b17-jpr-10-397" ref-type="bibr">17</xref> there was a significant improvement over the treatment period in pain manifestations as compared to the monotherapy group, although the patients within the monotherapy group also displayed significant improvement throughout the treatment as compared to pretreatment status. This finding and that of our study highlights the importance the vitamin B<sub>12</sub> component in the treatment of these painful conditions.</p><p>A limitation of this study was the inclusion of three distinct pain locations: lower back, hip, and carpal tunnel syndrome which ultimately reduced the number of subjects in each pain subcategory. Future studies should focus on a single pain location in order achieve more specific results. Nevertheless, we believe the results of this study are in concordance with findings in the literature and serve to contribute to the growing body of evidence indicating the therapeutic value of the combination of UTP,CMP and vitamin B12 for the treatment of peripheral neuropathies. It is also important to point out that unlike vitamin B<sub>12</sub> (which has been confirmed to exhibit antinociceptive effects in both animal and human studies) the nucleotides do not have any direct role in anti-inflammation or analgesia and thus the symptomatic improvements observed in our study and in previous studies are suggestive of structural neuroregeneration by the nucleotides as a mechanism of action.<xref rid="b10-jpr-10-397" ref-type="bibr">10</xref>, <xref rid="b11-jpr-10-397" ref-type="bibr">11</xref>, <xref rid="b14-jpr-10-397" ref-type="bibr">14</xref>, <xref rid="b15-jpr-10-397" ref-type="bibr">15</xref> Indeed, previous studies on animal models give credence to this notion, with previous observations of the nucleotides playing a positive role in axon and myelin sheaths of nerve and muscle fibers during regeneration following experimentally-induced damage, in addition to improved nerve fiber conduction velocity.<xref rid="b19-jpr-10-397" ref-type="bibr">19</xref>&#x02013;<xref rid="b21-jpr-10-397" ref-type="bibr">21</xref></p><p>A combination of uridine, folic acid, and vitamin B<sub>12</sub> was recently reported to be effective in the treatment of carpal tunnel syndrome. Although in a small scale exploratory trial of 48 subjects, authors reported reduced pain scores and improvement in symptom intensity following 60 days of treatment with the combination therapy.<xref rid="b23-jpr-10-397" ref-type="bibr">23</xref> An important limiting factor in our study with regards to carpal tunnel syndrome is the relatively small sample size in relation to the total patient population, as mentioned in the preceding paragraph. However, these findings together with the results of our study warrant further investigation into the use of the nucleotides and vitamin B<sub>12</sub> in the treatment of this very common ailment.</p><p>Clinical trials of painful conditions attributable to neuropathic pain (pain following neurological surgical procedures, neural compression-induced neuralgias, chronic neuropathic lumbar pain, peripheral neuropathies, and pain and paresthesia related to B<sub>12</sub> deficiency anemia) have consistently yielded encouraging results with use of the combination of uridine, cytidine, and vitamin B<sub>12</sub>, and further studies may reveal additional indications where this combination or others like it may be of use, while also expanding our understanding of the interaction between the nucleotides and vitamin B<sub>12</sub> in painful conditions.<xref rid="b9-jpr-10-397" ref-type="bibr">9</xref>&#x02013;<xref rid="b21-jpr-10-397" ref-type="bibr">21</xref> For instance, the combination of uridine, folic acid, and vitamin B<sub>12</sub> was also reported to be effective in neuropathic pain of peripheral neuropathies, with a reduction in pain intensity and also allowing for reduction in concomitant medication use.<xref rid="b23-jpr-10-397" ref-type="bibr">23</xref>,<xref rid="b24-jpr-10-397" ref-type="bibr">24</xref> These types of study are important to explore new alternatives for addressing neuropathic pain &#x02013; with the aim of providing treatment options that reduce pain, decreased need for other drugs with more unwanted side effects, and improve patient care and quality of life.</p></sec><sec><title>Conclusion</title><p>The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the combination of nucleotides + vitamin B<sub>12</sub>, with a statistically significant superiority of the combination in pain reduction (evidenced by VAS scores). There were adverse events in both treatment groups, but these were transitory and no severe adverse event was recorded during the study period. Safety parameters were maintained throughout the study in both treatment groups. The combination of uridine, cytidine, and vitamin B<sub>12</sub> was safe and effective in the treatment of neuralgias arising from neural compression associated with degenerative orthopedic alterations and trauma. Considering these results, a prospective, multi-center randomized controlled clinical trial, comparing the activity of vitamin B<sub>12</sub> alone to the activity of vitamin B<sub>12</sub> in combination with nucleotides in pain reduction, is warranted.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Renato Kaufman and Adenilson de Souza da Fonseca for participation in the study with subject recruitment, treatment, data review and contributions to the drafts of this paper. Thanks also to Alessandra Santos for clinical research form and data verification, and Daiane Bergamim, Silvia Maciel, Breno Lorch and Aline Pacheco for study monitoring.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-jpr-10-397"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Voet</surname><given-names>JG</given-names></name><name><surname>Pratt</surname><given-names>CW</given-names></name></person-group><source>Fundamentals of biochemistry: Life at the molecular level</source><publisher-loc>Hoboken, NJ</publisher-loc><publisher-name>Wiley</publisher-name><year>2008</year></element-citation></ref><ref id="b2-jpr-10-397"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name></person-group><article-title>Vitamin B12 deficiency</article-title><source>Am Fam Phys</source><year>2003</year><volume>67</volume><fpage>979</fpage><lpage>986</lpage></element-citation></ref><ref id="b3-jpr-10-397"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schjonsby</surname><given-names>H</given-names></name></person-group><article-title>Vitamin B12 absorption and malabsorption</article-title><source>Gut</source><year>1989</year><volume>30</volume><fpage>1986</fpage><lpage>1991</lpage></element-citation></ref><ref id="b4-jpr-10-397"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>JA</given-names></name></person-group><article-title>Vitamin deficiency and excess</article-title><source>Harrison&#x02019;s Principles of Internal Medicine</source><edition>14th Ed</edition><person-group person-group-type="editor"><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Isselbacher</surname><given-names>K</given-names></name><etal/></person-group><publisher-name>McGraw-Hill</publisher-name><publisher-loc>New York</publisher-loc><year>1998</year><fpage>481</fpage></element-citation></ref><ref id="b5-jpr-10-397"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gubler</surname><given-names>CJ</given-names></name></person-group><source>Handbook of vitamins: Nutritional, biochemical, and clinical aspects</source><person-group person-group-type="editor"><name><surname>Machlin</surname><given-names>LJ</given-names></name></person-group><publisher-name>Marcel Dekker</publisher-name><publisher-loc>New York</publisher-loc><year>1984</year><fpage>245</fpage></element-citation></ref><ref id="b6-jpr-10-397"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>RH</given-names></name><name><surname>Stabler</surname><given-names>SP</given-names></name><name><surname>Savage</surname><given-names>DG</given-names></name><name><surname>Lindenbaum</surname><given-names>J</given-names></name></person-group><article-title>Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency</article-title><source>FASEB J</source><year>1993</year><volume>7</volume><fpage>1344</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">7901104</pub-id></element-citation></ref><ref id="b7-jpr-10-397"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmel</surname><given-names>R</given-names></name></person-group><article-title>Current concepts in cobalamin deficiency</article-title><source>Ann Rev Med</source><year>2000</year><volume>51</volume><fpage>357</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10774470</pub-id></element-citation></ref><ref id="b8-jpr-10-397"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sechi</surname><given-names>G</given-names></name><name><surname>Sechi</surname><given-names>ES</given-names></name><name><surname>Fois</surname><given-names>C</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults</article-title><source>Nutr Rev</source><year>2016</year><volume>74</volume><issue>5</issue><fpage>281</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">27034475</pub-id></element-citation></ref><ref id="b9-jpr-10-397"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallai</surname><given-names>V</given-names></name><name><surname>Mazzotta</surname><given-names>G</given-names></name><name><surname>Montesi</surname><given-names>S</given-names></name><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Del Gatto</surname><given-names>F</given-names></name></person-group><article-title>Effects of uridine in the treatment of diabetic neuropathy: an electrophysiologic study</article-title><source>Acta Neurol Scandinav</source><year>1992</year><volume>86</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1325728</pub-id></element-citation></ref><ref id="b10-jpr-10-397"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>H</given-names></name><name><surname>Scussel Jr</surname><given-names>AR</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12</article-title><source>Rev Bras Med</source><year>2009</year><volume>66</volume><issue>11</issue><fpage>380</fpage><lpage>385</lpage></element-citation></ref><ref id="b11-jpr-10-397"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauretti</surname><given-names>GR</given-names></name><name><surname>Omais</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Mattos</surname><given-names>AL</given-names></name></person-group><article-title>Avalia&#x000e7;&#x000e3;o cl&#x000ed;nica do efeito analg&#x000e9;sico do complexo citidina-uridina-hidroxocobalamina como coadjuvante no tratamento da dor lombar cr&#x000f4;nica neurop&#x000e1;tica [Clinical evaluation of the cytidine-uridine-hydroxicobalamine complex as adjuvant in the management of the chronic neuropathic low back pain]</article-title><source>Coluna</source><year>2004</year><volume>3</volume><issue>2</issue><fpage>73</fpage><lpage>76</lpage><comment>Portuguese</comment></element-citation></ref><ref id="b12-jpr-10-397"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mibielli</surname><given-names>MA</given-names></name><name><surname>Nunes</surname><given-names>CP</given-names></name><name><surname>Cohen</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxocobalamin</article-title><source>Proc West Pharmacol Soc</source><year>2010</year><volume>53</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">22128442</pub-id></element-citation></ref><ref id="b13-jpr-10-397"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mibielli</surname><given-names>MA</given-names></name><name><surname>Nunes</surname><given-names>CP</given-names></name><name><surname>Scussel Jr</surname><given-names>AB</given-names></name><name><surname>Suchmacher Neto</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>L</given-names></name><name><surname>Geller</surname><given-names>M</given-names></name></person-group><article-title>Symptomatic improvement in an acute, non-traumatic spine pain model with a combination of uridine triphosphate, cytidine mono-phosphate, and hydroxocobalamin</article-title><source>PST</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>6</fpage><lpage>10</lpage></element-citation></ref><ref id="b14-jpr-10-397"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>D</given-names></name></person-group><article-title>Weniger Schmerzen bei diabetischer polyneuropathie. [Pilot study with pyrimidine nucleotides. Less pain in diabetic polyneuropathy]</article-title><source>MMW Fortschr der Med</source><year>2002</year><volume>144</volume><issue>46</issue><fpage>61</fpage><comment>German</comment></element-citation></ref><ref id="b15-jpr-10-397"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>D</given-names></name></person-group><article-title>Therapie de neuropathischen schemerzsyndroms: Ergebnisse einer offenen studie zur wirksamkeit eines pyrimidinnukleotid-Praparats. [Treatment of neuropathic pain syndrome. Results of an open study on the efficacy of a pyrimide nucleotide preparation]</article-title><source>Fortschr der Med Orig</source><year>2002</year><volume>120</volume><issue>4</issue><fpage>131</fpage><lpage>133</lpage><comment>German</comment></element-citation></ref><ref id="b16-jpr-10-397"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>CP</given-names></name><name><surname>Higashi</surname><given-names>R</given-names></name><name><surname>Ribeiro</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of a combination of uridine, cytidine, and vitamin B12 in anemia. A double-blind, comparative study versus nucleotide monotherapy</article-title><source>Rev Bras Med</source><year>2008</year><volume>65</volume><fpage>15</fpage><lpage>21</lpage></element-citation></ref><ref id="b17-jpr-10-397"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>CP</given-names></name><name><surname>Scussel</surname><given-names>AB</given-names><suffix>Jr</suffix></name><name><surname>Goldberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Alcoholic polyneuropathy: clinical assessment of treatment outcomes following therapy with nucleotides and vitamin B12</article-title><source>Res Neurol Inter J</source><year>2013</year><volume>2013</volume></element-citation></ref><ref id="b18-jpr-10-397"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>JP</given-names></name><name><surname>Veciana</surname><given-names>MG</given-names></name><name><surname>Bordas</surname><given-names>LB</given-names></name></person-group><article-title>Efectos terap&#x000e9;uticos de una asociaci&#x000f3;n de C.M.P., U.T.P., y vitamina B12 en cincuenta casos de neuropatias perifericas. [Therapeutic results of an association of CMP, UTP and vitamin B12 in 50 cases of peripheral neuropathy]</article-title><source>N Engl J Med (Spanish Edition)</source><year>1972</year><volume>VI</volume><issue>64</issue><fpage>1</fpage><lpage>7</lpage><comment>Spanish</comment></element-citation></ref><ref id="b19-jpr-10-397"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattig</surname><given-names>B</given-names></name><name><surname>Heydenreich</surname><given-names>F</given-names></name><name><surname>Schalow</surname><given-names>G</given-names></name><name><surname>Radzewitz</surname><given-names>B</given-names></name><name><surname>Warzok</surname><given-names>R</given-names></name><name><surname>Cerv&#x000f3;s-Navarro</surname><given-names>J</given-names></name></person-group><article-title>Nucleotide beschleunigen die nervenregeneration [Nucloetides accelerate nerve regeneration]</article-title><source>Z Klin Med</source><year>1991</year><volume>46</volume><fpage>1371</fpage><lpage>1373</lpage><comment>German</comment></element-citation></ref><ref id="b20-jpr-10-397"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattig</surname><given-names>B</given-names></name><name><surname>Schalow</surname><given-names>G</given-names></name><name><surname>Heydenreich</surname><given-names>F</given-names></name><name><surname>Warzok</surname><given-names>R</given-names></name><name><surname>Cerv&#x000f3;s-Navarro</surname><given-names>J</given-names></name></person-group><article-title>Enhancement of nerve fibre regeneration by nucleotides after peripheral nerve crush damage. Electrophysiologic and morphometric investigations</article-title><source>Arzneimittel-Forschung/Drug Research</source><year>1992</year><volume>42(II)</volume><issue>9</issue><fpage>1075</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">1445472</pub-id></element-citation></ref><ref id="b21-jpr-10-397"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattig</surname><given-names>B</given-names></name><name><surname>Schalow</surname><given-names>G</given-names></name><name><surname>Madauss</surname><given-names>M</given-names></name><name><surname>Heydenreich</surname><given-names>F</given-names></name><name><surname>Warzok</surname><given-names>R</given-names></name><name><surname>Cervos-Navarro</surname><given-names>J</given-names></name></person-group><article-title>Acceleration of nerve and muscle regeneration by administration of nucleotides &#x02013; electroneurophysiological and morphometrical investigations</article-title><source>Acta Histochemica</source><year>1992</year><volume>42</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">1584985</pub-id></element-citation></ref><ref id="b22-jpr-10-397"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Ulus</surname><given-names>IH</given-names></name><name><surname>Cansev</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Marzloff</surname><given-names>G</given-names></name></person-group><article-title>Synaptic proteins and phospholipids are increased in the gerbil brain by administering uridine plus docosahexanoic acid orally</article-title><source>Brain Res</source><year>2006</year><volume>1088</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">16631143</pub-id></element-citation></ref><ref id="b23-jpr-10-397"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negr&#x000e3;o</surname><given-names>L</given-names></name><name><surname>Almeida</surname><given-names>P</given-names></name><name><surname>Alcino</surname><given-names>S</given-names></name><name><surname>Duro</surname><given-names>H</given-names></name><name><surname>Lib&#x000f3;rio</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies</article-title><source>Pain Manag</source><year>2014</year><volume>4</volume><issue>3</issue><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">24835269</pub-id></element-citation></ref><ref id="b24-jpr-10-397"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negr&#x000e3;o</surname><given-names>L</given-names></name><name><surname>Nunes</surname><given-names>P</given-names></name></person-group><article-title>Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies</article-title><source>Pain Manag</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">26679082</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-jpr-10-397" position="float"><label>Figure 1</label><caption><p>Flowchart of subjects through the study</p></caption><graphic xlink:href="jpr-10-397Fig1"/></fig><fig id="f2-jpr-10-397" position="float"><label>Figure 2</label><caption><p>Patient overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment groups A and B at each study visit.</p><p><bold>Note:</bold> Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p></caption><graphic xlink:href="jpr-10-397Fig2"/></fig><fig id="f3-jpr-10-397" position="float"><label>Figure 3</label><caption><p>Physician overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment groups A and B at each study visit.</p><p><bold>Note:</bold> Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p></caption><graphic xlink:href="jpr-10-397Fig3"/></fig><fig id="f4-jpr-10-397" position="float"><label>Figure 4</label><caption><p>Visual analog scale scores for pain, for treatment groups A and B. <bold>Note:</bold> Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p><p><bold>Abbreviations:</bold> PT, pretreatment; VAS, visual analog scale; V2, visit two (after 15 days of treatment); V3, visit three (after 30 days of treatment).</p></caption><graphic xlink:href="jpr-10-397Fig4"/></fig><table-wrap id="t1-jpr-10-397" position="float"><label>Table 1</label><caption><p>Pretreatment and demographic data</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Variable</th><th colspan="3" valign="top" align="left" rowspan="1">Results
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Group A</th><th valign="top" align="left" rowspan="1" colspan="1">Group B</th><th valign="top" align="left" rowspan="1" colspan="1">Between-group difference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.6998</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">98</td><td valign="top" align="left" rowspan="1" colspan="1">114</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">102</td><td valign="top" align="left" rowspan="1" colspan="1">86</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">43.74 (&#x000b1;9.73)</td><td valign="top" align="left" rowspan="1" colspan="1">44.12 (&#x000b1;10.22)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.133</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (cm)</td><td valign="top" align="left" rowspan="1" colspan="1">166.91 (&#x000b1;9.23)</td><td valign="top" align="left" rowspan="1" colspan="1">168.49 (&#x000b1;8.86)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.0824</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.314</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Asian</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Black</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">83</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Caucasian</td><td valign="top" align="left" rowspan="1" colspan="1">90</td><td valign="top" align="left" rowspan="1" colspan="1">86</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mulatto</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pain location</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.5112</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Back pain</td><td valign="top" align="left" rowspan="1" colspan="1">125</td><td valign="top" align="left" rowspan="1" colspan="1">127</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Hip pain</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Carpal tunnel syndrome</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall diet</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.415</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Good</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">87</td><td valign="top" align="left" rowspan="1" colspan="1">99</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Poor</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alcohol consumption</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">63</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02264;2 drinks/day</td><td valign="top" align="left" rowspan="1" colspan="1">82</td><td valign="top" align="left" rowspan="1" colspan="1">73</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;2 drinks/day</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cigarette smoking</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.102</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Non-smoker</td><td valign="top" align="left" rowspan="1" colspan="1">91</td><td valign="top" align="left" rowspan="1" colspan="1">78</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;10 cigarettes/day</td><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;10 cigarettes/day</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Manual labor</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.309</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Light</td><td valign="top" align="left" rowspan="1" colspan="1">57</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">69</td><td valign="top" align="left" rowspan="1" colspan="1">56</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Heavy</td><td valign="top" align="left" rowspan="1" colspan="1">74</td><td valign="top" align="left" rowspan="1" colspan="1">76</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Physical exercise</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>=0.415</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Regular (at least 1&#x000d7;/week)</td><td valign="top" align="left" rowspan="1" colspan="1">49</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Irregular</td><td valign="top" align="left" rowspan="1" colspan="1">81</td><td valign="top" align="left" rowspan="1" colspan="1">77</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="left" rowspan="1" colspan="1">82</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-jpr-10-397"><p><bold>Notes:</bold> Data are n, or mean (&#x000b1;standard deviation). Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-jpr-10-397" position="float"><label>Table 2</label><caption><p>Safety assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Parameters</th><th colspan="2" valign="top" align="left" rowspan="1">Results
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Group A</th><th valign="top" align="left" rowspan="1" colspan="1">Group B</th></tr></thead><tbody><tr><td colspan="3" valign="top" align="left" rowspan="1">Weight (kg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pretreatment</td><td valign="top" align="left" rowspan="1" colspan="1">72.27 (&#x000b1;12.29)</td><td valign="top" align="left" rowspan="1" colspan="1">74.05 (&#x000b1;12.27)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit two</td><td valign="top" align="left" rowspan="1" colspan="1">72.35 (&#x000b1;12.28</td><td valign="top" align="left" rowspan="1" colspan="1">73.87 (&#x000b1;12.29)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit three</td><td valign="top" align="left" rowspan="1" colspan="1">72.42 (&#x000b1;12.31)</td><td valign="top" align="left" rowspan="1" colspan="1">74.04 (&#x000b1;12.39)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">BMI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pretreatment</td><td valign="top" align="left" rowspan="1" colspan="1">25.80 (&#x000b1;3.03)</td><td valign="top" align="left" rowspan="1" colspan="1">25.99 (&#x000b1;3.05)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit two</td><td valign="top" align="left" rowspan="1" colspan="1">25.80 (&#x000b1;3.013)</td><td valign="top" align="left" rowspan="1" colspan="1">25.96 (&#x000b1;3.099)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit three</td><td valign="top" align="left" rowspan="1" colspan="1">25.82 (&#x000b1;3.009)</td><td valign="top" align="left" rowspan="1" colspan="1">26.02 (&#x000b1;3.121)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Systolic blood pressure (mmHg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pretreatment</td><td valign="top" align="left" rowspan="1" colspan="1">123.7 (&#x000b1;8.541)</td><td valign="top" align="left" rowspan="1" colspan="1">123.7 (&#x000b1;7.285)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit two</td><td valign="top" align="left" rowspan="1" colspan="1">122.4 (&#x000b1;7.376)</td><td valign="top" align="left" rowspan="1" colspan="1">122.7 (&#x000b1;8.124)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit three</td><td valign="top" align="left" rowspan="1" colspan="1">122.4 (&#x000b1;7.813)</td><td valign="top" align="left" rowspan="1" colspan="1">123.0 (&#x000b1;7.644)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Diastolic blood presssure (mmHg)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pretreatment</td><td valign="top" align="left" rowspan="1" colspan="1">80.29 (&#x000b1;7.42)</td><td valign="top" align="left" rowspan="1" colspan="1">80.14 (&#x000b1;8.269)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit two</td><td valign="top" align="left" rowspan="1" colspan="1">79.67 (&#x000b1;7.755)</td><td valign="top" align="left" rowspan="1" colspan="1">79.43 (&#x000b1;8.655)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit three</td><td valign="top" align="left" rowspan="1" colspan="1">80.04 (&#x000b1;7.576)</td><td valign="top" align="left" rowspan="1" colspan="1">79.38 (&#x000b1;8.672)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Pulse (bpm)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pretreatment</td><td valign="top" align="left" rowspan="1" colspan="1">68.54 (&#x000b1;4.644)</td><td valign="top" align="left" rowspan="1" colspan="1">68.92 (&#x000b1;4.503)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit two</td><td valign="top" align="left" rowspan="1" colspan="1">68.17 (&#x000b1;5.165)</td><td valign="top" align="left" rowspan="1" colspan="1">68.47 (&#x000b1;5.647)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Visit three</td><td valign="top" align="left" rowspan="1" colspan="1">68.30 (&#x000b1;4.789)</td><td valign="top" align="left" rowspan="1" colspan="1">68.57 (&#x000b1;4.648)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-jpr-10-397"><p><bold>Notes:</bold> Data are n, or mean (&#x000b1;standard deviation). Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p></fn><fn id="tfn3-jpr-10-397"><p><bold>Abbreviations:</bold> BMI, body mass index; bpm, beats per minute.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-jpr-10-397" position="float"><label>Table 3</label><caption><p>Adverse events considered to be associated with study drug administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Adverse event</th><th valign="top" align="left" rowspan="1" colspan="1">Severity</th><th valign="top" align="left" rowspan="1" colspan="1">Number of affected subjects</th></tr></thead><tbody><tr><td colspan="3" valign="top" align="left" rowspan="1"><bold>Group A</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal colic</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal discomfort</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal distension</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal distension</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal disturbance</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Feeling of bloating</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Flatulence</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Increased appetite</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">3</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1"><bold>Group B</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal discomfort</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal distension</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal distension</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Constipation</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Constipation</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elevated uric acid</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epigastralgia</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epigastralgia</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Flatulence</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-jpr-10-397"><p><bold>Note:</bold> Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.</p></fn></table-wrap-foot></table-wrap></floats-group></article>